{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T21:21:57Z","timestamp":1783718517438,"version":"3.55.0"},"reference-count":42,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T00:00:00Z","timestamp":1664409600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015900","name":"OVC Pet Trust","doi-asserted-by":"publisher","award":["054720"],"award-info":[{"award-number":["054720"]}],"id":[{"id":"10.13039\/100015900","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015900","name":"OVC Pet Trust","doi-asserted-by":"publisher","award":["053650"],"award-info":[{"award-number":["053650"]}],"id":[{"id":"10.13039\/100015900","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Urokinase plasminogen activator (uPA) and its receptor uPAR promote cancer invasion and metastasis and are emerging therapeutic targets in both human and canine malignancies. While their clinical significance is well-characterized in multiple human tumor types, studies investigating their roles in osteosarcoma are lacking. The objectives of this study were to characterize serum and tissue uPA\/uPAR expression in dogs with osteosarcoma and assess the prognostic significance. Serum samples and a tissue microarray of canine appendicular osteosarcoma were analyzed for uPA and uPAR expression by ELISA (n = 49) and immunohistochemistry (n = 38), respectively. Serum uPA activity was also measured by a chromogenic assay (n = 25). Survival analysis was performed by Kaplan-Meier survival analysis, log rank test, and Cox regression analysis. Serum uPA level was significantly higher in dogs with osteosarcoma than clinically healthy control dogs (median 1905 vs 1440 pg\/ml, p = 0.008). The majority of canine osteosarcoma tissues expressed uPA (75.9%) or uPAR (77.6%), with 70.7% dual-positivity, indicating autocrine\/paracrine activation of the pathway. Survival analysis revealed shorter progression free survival (PFS) in dogs with high serum uPA level in a discovery cohort (n = 29; median PFS 94 vs 266 days, p = 0.003) but not in a validation cohort (n = 23; median PFS 167 vs 490 days, p = 0.16). The difference was significant when both cohorts were combined (n = 49; median PFS 128 vs 266 days, p = 0.003). Serum uPAR and tissue uPA\/uPAR levels were not prognostic. In Cox multivariate analysis, high serum uPA level and activity were both associated with poor prognosis, independent of serum ALP, tumor location, and peripheral lymphocyte\/monocyte counts. These results indicate high utilization of the uPA pathway and association with disease progression in canine osteosarcoma. Further study involving prospective evaluation to confirm the prognostic significance is warranted. The high prevalence of tissue uPA and uPAR expression suggests the uPA system as a potential therapeutic target in canine osteosarcoma.<\/jats:p>","DOI":"10.1371\/journal.pone.0273811","type":"journal-article","created":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T19:23:48Z","timestamp":1664479428000},"page":"e0273811","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["Prognostic significance of the urokinase plasminogen activator system in tissue and serum of dogs with appendicular osteosarcoma"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8314-5656","authenticated-orcid":true,"given":"Arata","family":"Matsuyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1756-8607","authenticated-orcid":true,"given":"Geoffrey A.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael","family":"Speare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney R.","family":"Schott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7965-7149","authenticated-orcid":true,"given":"Anthony J.","family":"Mutsaers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,9,29]]},"reference":[{"issue":"7","key":"pone.0273811.ref001","doi-asserted-by":"crossref","first-page":"995","DOI":"10.2460\/javma.1992.200.07.995","article-title":"Prognosis for dogs with appendicular osteosarcoma treated by amputation alone: 162 cases (1978\u20131988).","volume":"200","author":"G Spodnick","year":"1992","journal-title":"J Am Vet Med Assoc"},{"issue":"4","key":"pone.0273811.ref002","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1939-1676.1988.tb00313.x","article-title":"Treatment by Amputation Versus Amputation and Adjuvant Chemotherapy Using Doxorubicin and Cisplatin","volume":"2","author":"GN Mauldin","year":"1988","journal-title":"J Vet Intern Med"},{"issue":"2","key":"pone.0273811.ref003","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1939-1676.1996.tb02031.x","article-title":"Amputation and Carboplatin for Treatment of Dogs With Osteosarcoma: 48 Cases (1991 to 1993).","volume":"10","author":"PJ Bergman","year":"1996","journal-title":"J Vet Intern Med"},{"issue":"2","key":"pone.0273811.ref004","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1939-1676.2003.tb02434.x","article-title":"Carboplatin and Doxorubicin Combination Chemotherapy for the Treatment of Appendicular Osteosarcoma in the Dog","volume":"17","author":"D Bailey","year":"2003","journal-title":"J Vet Intern Med"},{"issue":"6","key":"pone.0273811.ref005","doi-asserted-by":"crossref","first-page":"382","DOI":"10.5326\/0410382","article-title":"Toxicity and Efficacy of Cisplatin and Doxorubicin Combination Chemotherapy for the Treatment of Canine Osteosarcoma.","volume":"41","author":"R Chun","year":"2005","journal-title":"J Am Anim Hosp Assoc.Nov 1"},{"issue":"1","key":"pone.0273811.ref006","doi-asserted-by":"crossref","first-page":"33","DOI":"10.5326\/0450033","article-title":"Use of Single-Agent Carboplatin as Adjuvant or Neoadjuvant Therapy in Conjunction With Amputation for Appendicular Osteosarcoma in Dogs.","volume":"45","author":"B Phillips","year":"2009","journal-title":"J Am Anim Hosp Assoc.Jan"},{"issue":"1","key":"pone.0273811.ref007","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/vco.12069","article-title":"Carboplatin versus alternating carboplatin and doxorubicin for the adjuvant treatment of canine appendicular osteosarcoma: a randomized, phase III trial: Chemotherapy for osteosarcoma.","volume":"14","author":"KA Skorupski","year":"2016","journal-title":"Vet Comp Oncol.Mar"},{"key":"pone.0273811.ref008","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3389\/fonc.2018.00024","article-title":"Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications.","volume":"8","author":"N Mahmood","year":"2018","journal-title":"Front Oncol."},{"issue":"19","key":"pone.0273811.ref009","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.2174\/138161211796718215","article-title":"The Urokinase Receptor Interactome.","volume":"17","author":"G Eden","year":"2011","journal-title":"Curr Pharm Des"},{"issue":"1","key":"pone.0273811.ref010","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1182\/blood-2007-07-104455","article-title":"Nuclear translocation of urokinase-type plasminogen activator","volume":"112","author":"V Stepanova","year":"2008","journal-title":"Blood"},{"issue":"29","key":"pone.0273811.ref011","doi-asserted-by":"crossref","first-page":"15029","DOI":"10.1074\/jbc.M115.678490","article-title":"Urokinase-type Plasminogen Activator (uPA) Promotes Angiogenesis by Attenuating Proline-rich Homeodomain Protein (PRH) Transcription Factor Activity and De-repressing Vascular Endothelial Growth Factor (VEGF) Receptor Expression.","volume":"291","author":"V Stepanova","year":"2016","journal-title":"J Biol Chem"},{"issue":"24","key":"pone.0273811.ref012","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1016\/S0960-9822(00)80116-5","article-title":"Urokinase-induced mitogenesis is mediated by casein kinase 2 and nucleolin","volume":"9","author":"I Dumler","year":"1999","journal-title":"Curr Biol"},{"issue":"3","key":"pone.0273811.ref013","doi-asserted-by":"crossref","first-page":"213","DOI":"10.5858\/1999-123-0213-PEIDPO","article-title":"Protease Expression in Dedifferentiated Parosteal Osteosarcoma","volume":"123","author":"C Haeckel","year":"1999","journal-title":"Arch Pathol Lab Med"},{"issue":"6","key":"pone.0273811.ref014","first-page":"1654","article-title":"The Expression of the Urokinase Plasminogen Activator System in Metastatic Murine Osteosarcoma: An in Vivo Mouse Model","volume":"7","author":"JL Fisher","year":"2001","journal-title":"Clin Cancer Res"},{"key":"pone.0273811.ref015","article-title":"Progression of Osteosarcoma from a Non-Metastatic to a Metastatic Phenotype Is Causally Associated with Activation of an Autocrine and Paracrine uPA Axis.","volume":"22","author":"L Endo-Munoz","year":"2015"},{"issue":"5","key":"pone.0273811.ref016","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1158\/1535-7163.MCT-16-0637","article-title":"Safe and Effective Sarcoma Therapy through Bispecific Targeting of EGFR and uPAR","volume":"16","author":"A Borgatti","year":"2017","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"pone.0273811.ref017","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/sj.bjc.6605520","article-title":"Co-detection of members of the urokinase plasminogen activator system in tumour tissue and serum correlates with a poor prognosis for soft-tissue sarcoma patients","volume":"102","author":"H Taubert","year":"2010","journal-title":"Br J Cancer"},{"issue":"12","key":"pone.0273811.ref018","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1093\/jnci\/93.12.913","article-title":"Randomized Adjuvant Chemotherapy Trial in High-Risk, Lymph Node-Negative Breast Cancer Patients Identified by Urokinase-Type Plasminogen Activator and Plasminogen Activator Inhibitor Type 1","volume":"93","author":"F Janicke","year":"2001","journal-title":"JNCI J Natl Cancer Inst"},{"issue":"2","key":"pone.0273811.ref019","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/jnci\/94.2.116","article-title":"Pooled Analysis of Prognostic Impact of Urokinase-Type Plasminogen Activator and Its Inhibitor PAI-1 in 8377 Breast Cancer Patients","volume":"94","author":"MP Look","year":"2002","journal-title":"JNCI J Natl Cancer Inst"},{"issue":"8","key":"pone.0273811.ref020","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/j.ejca.2013.01.007","article-title":"Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients.","volume":"49","author":"N Harbeck","year":"2013","journal-title":"Eur J Cancer"},{"issue":"4","key":"pone.0273811.ref021","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/(SICI)1097-0215(19960822)69:4<268::AID-IJC5>3.0.CO;2-V","article-title":"Urokinase-plasminogen-activator levels and prognosis in 69 soft-tissue sarcomas","volume":"69","author":"PFM Choong","year":"1996","journal-title":"Int J Cancer"},{"issue":"05","key":"pone.0273811.ref022","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1055\/s-0037-1614558","article-title":"Blast Cell-surface and Plasma Soluble Urokinase Receptor in Acute Leukemia Patients: Relationship to Classification and Response to Therapy","volume":"81","author":"S Mustjoki","year":"1999","journal-title":"Thromb Haemost"},{"issue":"33","key":"pone.0273811.ref023","doi-asserted-by":"crossref","first-page":"5287","DOI":"10.1200\/JCO.2007.14.2364","article-title":"American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer.","volume":"25","author":"L Harris","year":"2007","journal-title":"J Clin Oncol"},{"issue":"3\u20134","key":"pone.0273811.ref024","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1155\/2009\/504294","article-title":"suPAR: The Molecular Crystal Ball.","volume":"27","author":"M Thun\u00f8","year":"2009","journal-title":"Dis Markers"},{"issue":"2","key":"pone.0273811.ref025","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1177\/0300985817747329","article-title":"Histologic Grade Does Not Predict Outcome in Dogs with Appendicular Osteosarcoma Receiving the Standard of Care","volume":"55","author":"CR Schott","year":"2018","journal-title":"Vet Pathol"},{"issue":"6","key":"pone.0273811.ref026","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1111\/j.1939-1676.2010.0591.x","article-title":"Association of Blood Monocyte and Lymphocyte Count and Disease-Free Interval in Dogs with Osteosarcoma: CBC is Prognostic in Osteosarcoma","volume":"24","author":"JL Sottnik","year":"2010","journal-title":"J Vet Intern Med"},{"issue":"1","key":"pone.0273811.ref027","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/1746-6148-8-56","article-title":"Prognostic factors in canine appendicular osteosarcoma\u2013a meta-analysis","volume":"8","author":"I Boerman","year":"2012","journal-title":"BMC Vet Res"},{"issue":"1","key":"pone.0273811.ref028","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1186\/s12917-018-1651-5","article-title":"An evaluation of TAZ and YAP crosstalk with TGF\u03b2 signalling in canine osteosarcoma suggests involvement of hippo signalling in disease progression","volume":"14","author":"AK Luu","year":"2018","journal-title":"BMC Vet Res"},{"issue":"1","key":"pone.0273811.ref029","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s12917-016-0707-7","article-title":"Effects of epidermal growth factor receptor kinase inhibition on radiation response in canine osteosarcoma cells","volume":"12","author":"FB Mantovani","year":"2016","journal-title":"BMC Vet Res"},{"issue":"21","key":"pone.0273811.ref030","doi-asserted-by":"crossref","first-page":"7252","DOI":"10.1158\/1078-0432.CCR-04-0713","article-title":"X-Tile: A New Bio-Informatics Tool for Biomarker Assessment and Outcome-Based Cut-Point Optimization","volume":"10","author":"RL Camp","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"5","key":"pone.0273811.ref031","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S1535-6108(02)00072-7","article-title":"EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma","volume":"1","author":"D Liu","year":"2002","journal-title":"Cancer Cell"},{"issue":"10","key":"pone.0273811.ref032","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1038\/sj.emboj.7600669","article-title":"Urokinase-induced signaling in human vascular smooth muscle cells is mediated by PDGFR-\u03b2","volume":"24","author":"J Kiyan","year":"2005","journal-title":"EMBO J"},{"issue":"8","key":"pone.0273811.ref033","doi-asserted-by":"crossref","first-page":"918","DOI":"10.14202\/vetworld.2017.918-923","article-title":"Serum levels of urokinase-type plasminogen activator in healthy dogs and oncologic canine patients.","volume":"10","author":"SC Ramos","year":"2017","journal-title":"Vet World."},{"issue":"4","key":"pone.0273811.ref034","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/ijc.20631","article-title":"Reduced metastasis of transgenic mammary cancer in urokinase-deficient mice: Urokinase Deficiency Reduces Metastasis","volume":"113","author":"K Almholt","year":"2005","journal-title":"Int J Cancer"},{"issue":"19","key":"pone.0273811.ref035","doi-asserted-by":"crossref","first-page":"12752","DOI":"10.1016\/S0021-9258(18)98963-5","article-title":"Plasminogen activation by receptor-bound urokinase. A kinetic study with both cell-associated and isolated receptor","volume":"266","author":"V Ellis","year":"1991","journal-title":"J Biol Chem"},{"issue":"29","key":"pone.0273811.ref036","doi-asserted-by":"crossref","first-page":"17375","DOI":"10.1074\/jbc.270.29.17375","article-title":"Enhancement of the Enzymatic Activity of Single-chain Urokinase Plasminogen Activator by Soluble Urokinase Receptor","volume":"270","author":"AA-R Higazi","year":"1995","journal-title":"J Biol Chem"},{"issue":"4\u20136","key":"pone.0273811.ref037","first-page":"731","article-title":"Biological and clinical relevance of the urokinase-type plasminogen activator (uPA) in breast cancer.","volume":"50","author":"M Schmitt","year":"1991","journal-title":"Biomed Biochim Acta"},{"issue":"7","key":"pone.0273811.ref038","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1182\/blood.V91.7.2305","article-title":"Vitronectin Concentrates Proteolytic Activity on the Cell Surface and Extracellular Matrix by Trapping Soluble Urokinase Receptor-Urokinase Complexes","volume":"91","author":"T Chavakis","year":"1998","journal-title":"Blood"},{"issue":"7","key":"pone.0273811.ref039","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1002\/j.1460-2075.1996.tb00502.x","article-title":"Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect","volume":"15","author":"M Resnati","year":"1996","journal-title":"EMBO J"},{"issue":"2","key":"pone.0273811.ref040","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/jcb.240530206","article-title":"Expression and localization of elements of the plasminogen activation system in benign breast disease and breast cancers","volume":"53","author":"J Jankun","year":"1993","journal-title":"J Cell Biochem"},{"issue":"4","key":"pone.0273811.ref041","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.jcpa.2015.07.003","article-title":"Immunohistochemical Detection of Urokinase Plasminogen Activator and Urokinase Plasminogen Activator Receptor in Canine Vascular Endothelial Tumours","volume":"153","author":"Anwar Sh","year":"2015","journal-title":"J Comp Pathol"},{"issue":"7","key":"pone.0273811.ref042","doi-asserted-by":"crossref","first-page":"e101895","DOI":"10.1371\/journal.pone.0101895","article-title":"Urokinase Plasminogen Activator Receptor (uPAR) and Plasminogen Activator Inhibitor-1 (PAI-1) Are Potential Predictive Biomarkers in Early Stage Oral Squamous Cell Carcinomas (OSCC).","volume":"9","author":"S Magnussen","year":"2014","journal-title":"PLoS ONE"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0273811","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T23:23:29Z","timestamp":1728084209000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0273811"}},"subtitle":[],"editor":[{"given":"Douglas H.","family":"Thamm","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,9,29]]},"references-count":42,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,9,29]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0273811","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,29]]}}}